By Michael Dabaie

Celularity Inc. said the U.S. Food and Drug Administration cleared its Investigational New Drug application for CYNK-101 in combination with standard chemotherapy, trastuzumab and pembrolizumab in advanced Her2/neu positive gastric and gastroesophageal junction cancer.

CYNK-101 is an investigational genetically engineered natural killer cell therapy designed to synergize with antibody therapeutics, the company said.

The Phase 1/2a clinical trial will evaluate safety and preliminary efficacy.

"Gastric cancer represents the fifth most common cancer worldwide, and in advanced stages of the disease, continues to be associated with less than desirable survival outcomes despite recent advances," said Chief Executive Robert Hariri.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

November 29, 2021 08:43 ET (13:43 GMT)